A Comprehensive Investment Playbook for Traders and Investors
The Indian pharmaceutical industry is evolving into one of the most critical growth engines of the economy. From being the world’s largest generic drug supplier to becoming a hub for biosimilars and clinical trials, the sector presents a strong mix of domestic consumption, export strength, and long-term innovation potential. For traders and investors, understanding the layered dynamics of this industry is key to spotting opportunities and managing risk.
This detailed outlook, based on Jainam Broking’s July 2025 Pharmaceutical Industry Report, breaks down the sector across demand drivers, exports, regulatory processes, manufacturing capacity, financial performance, and strategic risks—while retaining all original data and facts from the report.
India stands as a global leader in pharmaceutical production by volume (ranked 3rd) and maintains a significant position by value (ranked 14th). The industry includes over 3,000 pharmaceutical companies and around 10,500 manufacturing units, underpinned by a large pool of skilled scientists and engineers. As of FY24, the Indian pharmaceutical market is valued at US$ 65 billion, and it is expected to double to US$ 130 billion by FY30, with a long-term projection of US$ 450 billion by 2047.
The domestic industry spans multiple segments: generic drugs, OTC medicines, bulk drugs, vaccines, contract research, biosimilars, and biologics. This wide scope, along with competitive cost structures and regulatory strengths, supports the sector’s relevance both locally and internationally. The pharmaceutical sector also contributes approximately 1.72% to India’s GDP, highlighting its macroeconomic significance.
Why it matters: For investors, this scale and growth potential provide the basis for long-term capital appreciation, while for traders, India’s global leadership creates opportunities around export data releases, FDA approvals, and policy updates.
India’s pharmaceutical market is being reshaped by demographic trends and public health initiatives. Government schemes like Ayushman Bharat and PMJAY have expanded healthcare access to millions, triggering higher medicine consumption. At the same time, the country faces a rising burden of non-communicable diseases (NCDs) such as diabetes, hypertension, and cardiovascular disorders—necessitating long-term medication use.
Another key driver is the increase in government healthcare spending, which has grown from US$ 35.1 billion in FY17 to US$ 66.4 billion in FY23. Insurance penetration is improving, and awareness of preventive healthcare is rising even in Tier 2 and Tier 3 cities.
Why it matters: These long-term trends support a structurally growing domestic market, especially in chronic segments. Investors should watch for companies with strong domestic brand portfolios in anti-diabetic, cardiac, and respiratory therapies.
India’s pharma exports reached US$ 27.82 billion in FY24, growing from US$ 16.9 billion in FY16 at a 6% CAGR. The country now exports to over 200 countries, including regulated markets like the U.S., EU, Japan, and Australia. In FY24, the top five export destinations were the USA, UK, South Africa, Netherlands, and France.
The product mix of exports is heavily skewed towards drug formulations and biologicals (73.75%), followed by bulk drugs and intermediates (17.08%). Other export categories include vaccines (4.27%), Ayush & herbal products (2.33%), and surgicals (2.58%).
India also supplied 400 million tablets and 45 tonnes of hydroxychloroquine during global emergencies, showing its logistical capability.
Why it matters: Traders can leverage earnings seasons of export-heavy firms for short-term moves, while investors can back companies with high exposure to regulated markets and diversified product categories.
India’s domestic formulations market stood at ₹1.9 trillion in FY23 and is projected to grow at a CAGR of 9–10%, reaching ₹2.8–3.0 trillion by FY28. The market is split between chronic therapies (53%) and acute therapies (47%), with chronic segments expected to rise to 57% by FY28.
Therapy-wise, the fastest-growing categories include:
The shift toward chronic treatments indicates a structural change in India’s disease burden.
Why it matters: Investors should focus on companies with strong chronic portfolios, while traders can watch quarterly prescription growth trends and seasonal upticks (e.g., respiratory drugs in winter).
While generics continue to dominate, select Indian companies are making investments in original drug discovery, biosimilars, and complex generics. The drug development process—from target identification to FDA approval—takes 10–15 years and includes pre-clinical testing and three phases of human trials.
Indian companies investing in R&D include:
Global peers like Pfizer and Novartis spend 15–20% of revenue, so Indian firms are gradually catching up. Clinical trials (Phase 1–3) can cost ₹100–500 Cr per drug, making them capital-intensive.
Why it matters: Investors seeking high-margin potential and pipeline leverage can follow companies increasing R&D allocations, while traders can watch trial updates and licensing deals as event triggers.
Understanding New Drug Applications (NDA) and Abbreviated New Drug Applications (ANDA) is crucial.
In 2022, 223 companies globally received final ANDA approvals, demonstrating the continued expansion of the generic drug segment.
Why it matters: ANDA approvals drive export-led growth. Traders can react to approval announcements, while investors should track companies with high FDA filing activity.
India’s manufacturing process is vertically integrated—from key starting materials (e.g., benzene) to active pharmaceutical ingredients (APIs) to final formulations. For instance, in the production of Paracetamol, chemicals like Para Amino Phenol (PAP) are used to make the API, which is then converted into branded drugs like Dolo or Crocin.
The Indian API market was valued at US$ 13.6 billion in 2024 and is expected to reach US$ 18.8 billion by 2028 at an 8% CAGR. India has received 6,316 USFDA approvals for formulation plants—more than any other country.
Why it matters: Backward-integrated companies with API capabilities are better insulated from raw material cost shocks. Investors should monitor API capacity expansion plans, while traders can play capacity utilization themes.
India imports approximately 71% of API intermediates from China, a major risk factor for the industry. Disruptions in China, such as environmental shutdowns or logistical delays—as seen during Feb–Mar 2021—can impact production timelines and input costs.
Additionally, Chinese bulk drug firms receive government subsidies, which distort global pricing and put Indian firms at a margin disadvantage. Any future policy changes in China could lead to volatility in India’s pharmaceutical cost structures.
Why it matters: This is a high-impact risk that can affect earnings. Investors should prefer companies with domestic API sources or backward integration. Traders can monitor news around Chinese chemical sector disruptions for short-term plays.
In FY24, the top profit earners in the Indian pharmaceutical sector were:
These firms have established their leadership through strong export markets, diversified portfolios, and operational efficiencies. Their consistent profitability also reflects their compliance strength and scale advantages.
Why it matters: For investors, these are stable compounders. Traders can look at earnings season for upside surprises, especially when backed by regulatory approvals or R&D milestones.
India’s pharmaceutical industry is positioned for sustained growth, supported by:
However, challenges like China dependency, regulatory scrutiny, and R&D capital risks must be factored in. For traders, short-term opportunities arise from clinical updates, export data, and FDA approvals. For investors, companies with export strength, chronic therapy exposure, and rising R&D spend offer promising long-term bets.
This industry is not just recession-proof—it’s structurally primed for expansion.
Ready to capitalise on India’s pharma boom? Talk to our experts today!
The opinions and investment advice shared by financial experts on this platform are solely their own and do not represent the views of the website or its management. We strongly recommend consulting with certified professionals before making any investment decisions.
Join our 3 Cr+ happy customers
Know the mind behind this article
Open your free Demat account in minutes or explore partnership opportunities with Jainam.
Get the link to download the App
